D'Orazio & Associates’s Amgen AMGN Stock Holding History

D'Orazio & Associates’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.12M	Sell	3,096 -45	-1%	-$15.4K	0.13%	61
2026 Q1	$1.11M	Buy	3,141 +231	+8%	+$82.3K	0.14%	58
2025 Q4	$953K	Buy	2,910 +108	+4%	+$34.3K	0.12%	63
2025 Q3	$791K	Buy	2,802 +50	+2%	+$14.5K	0.1%	73
2025 Q2	$768K	Buy	2,752 +10	+0.4%	+$2.83K	0.11%	72
2025 Q1	$854K	Sell	2,742 -266	-9%	-$78.5K	0.13%	65
2024 Q4	$784K	Sell	3,008 -94	-3%	-$27.9K	0.12%	66
2024 Q3	$999K	Buy	3,102 +1	+0%	+$327	0.14%	58
2024 Q2	$969K	Buy	3,101 +33	+1%	+$9.7K	0.15%	53
2024 Q1	$872K	Buy	3,068 +12	+0.4%	+$3.51K	0.14%	58
2023 Q4	$880K	Buy	3,056 +50	+2%	+$13.6K	0.16%	51
2023 Q3	$808K	Buy	3,006 +627	+26%	+$156K	0.18%	51
2023 Q2	$528K	Sell	2,379 -844	-26%	-$196K	0.12%	61
2023 Q1	$779K	Sell	3,223 -1,040	-24%	-$255K	0.2%	40
2022 Q4	$1.12M	Buy	4,263 +936	+28%	+$251K	0.27%	32
2022 Q3	$750K	Sell	3,327 -349	-9%	-$84.6K	0.22%	34
2022 Q2	$894K	Buy	3,676 +873	+31%	+$214K	0.24%	32
2022 Q1	$678K	Buy	2,803 +506	+22%	+$116K	0.16%	40
2021 Q4	$517K	Sell	2,297 -98	-4%	-$20.7K	0.12%	50
2021 Q3	$509K	Buy	2,395 +412	+21%	+$94.8K	0.12%	47
2021 Q2	$483K	Hold	1,983	–	–	0.12%	47
2021 Q1	$493K	Buy	1,983 +333	+20%	+$79.5K	0.14%	43
2020 Q4	$379K	Buy	1,650 +120	+8%	+$27.7K	0.12%	50
2020 Q3	$389K	Hold	1,530	–	–	0.16%	42
2020 Q2	$361K	Hold	1,530	–	–	0.16%	42
2020 Q1	$310K	Hold	1,530	–	–	0.15%	41
2019 Q4	$369K	Hold	1,530	–	–	0.11%	44
2019 Q3	$296K	Sell	1,530 -56	-4%	-$10.7K	0.1%	51
2019 Q2	$292K	Sell	1,586 -9	-0.6%	-$1.61K	0.08%	48
2019 Q1	$303K	Buy	1,595 +65	+4%	+$12.4K	0.09%	46
2018 Q4	$298K	Hold	1,530	–	–	0.1%	41
2018 Q3	$317K	Hold	1,530	–	–	0.12%	44
2018 Q2	$282K	Hold	1,530	–	–	0.11%	44
2018 Q1	$261K	Buy	1,530 +50	+3%	+$9.18K	0.1%	41
2017 Q4	$257K	Hold	1,480	–	–	0.09%	46
2017 Q3	$276K	Hold	1,480	–	–	0.1%	38
2017 Q2	$255K	Hold	1,480	–	–	0.1%	39
2017 Q1	$243K	Hold	1,480	–	–	0.09%	39
2016 Q4	$216K	Hold	1,480	–	–	0.09%	39
2016 Q3	$246K	Hold	1,480	–	–	0.1%	36
2016 Q2	$225K	Hold	1,480	–	–	0.09%	42
2016 Q1	$221K	Hold	1,480	–	–	0.09%	41
2015 Q4	$240K	Sell	1,480 -200	-12%	-$31.4K	0.12%	31
2015 Q3	$266K	Hold	1,680	–	–	0.13%	29
2015 Q2	$258K	Hold	1,680	–	–	0.17%	29
2015 Q1	$269K	Buy	1,680 +100	+6%	+$15.7K	0.21%	31
2014 Q4	$252K	Hold	1,580	–	–	0.17%	29
2014 Q3	$222K	Hold	1,580	–	–	0.16%	31
2014 Q2	$187K	Hold	1,580	–	–	0.14%	37
2014 Q1	$195K	Hold	1,580	–	–	0.15%	29
2013 Q4	$180K	Buy	+1,580	New	+$180K	0.15%	31

Other funds holding AMGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

D'Orazio & Associates's AMGN Position: Q2 2026 in Review

D'Orazio & Associates reduced its Amgen (AMGN) stake by 1.4% in Q2 2026, selling an estimated $15.4K and leaving 3,096 shares worth $1.12M. The position accounts for 0.13% of the portfolio, ranked #61.

D'Orazio & Associates first reported a position in AMGN in Q4 2013 and has held it in 51 quarters since. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

D'Orazio & Associates held 3,096 shares of Amgen worth $1.12M as of Q2 2026.
D'Orazio & Associates sold 45 Amgen shares in Q2 2026, an estimated $15.4K.
Amgen made up 0.13% of D'Orazio & Associates's portfolio in Q2 2026, its #61 holding.
D'Orazio & Associates first reported a position in Amgen in Q4 2013 and has held it in 51 quarters since.
3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on D'Orazio & Associates's 13F filing for Q2 2026, filed 28 Jul 2026.